Benzinga | Oct 18, 2021 08:51AM EDT

DiaMedica Therapeutics Highlights Late-Breaking Data From Phase 2 REDUX Trial Of Its Chronic Kidney Disease Candidate At American Society Of Nephrology Kidney Meeting Nov. 4 At 1 p.m. EDT

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that late-breaking data from the Company's Phase 2 REDUX trial of DM199 in chronic kidney disease (CKD) will be presented at the American Society of Nephrology's (ASN) annual Kidney Week meeting. The abstract will include an update to the Phase 2 REDUX interim data the Company announced in June 2021.

The ePoster session details are:

Session Title: Late-Breaking Clinical Trials Posters

Session Release Date: Thursday, November 4, 10:00 a.m. PDT (Pacific)

ePoster number: PO2526

The ASN Kidney Week 2021 will held virtually November 4-7, 2021. Additional information can be found here.